Director, Nonclinical Due Diligence & External Innovation

Location: Zurich, Switzerland or Waltham, USA; onsite presence required 3 days per week

Company

hirify.global is a global biotherapeutics company developing and delivering therapies for rare and serious diseases, including immunology, hematology, cardiovascular, metabolic, respiratory, and transplant conditions.

What you will do

• Lead end-to-end nonclinical due diligence for individual assets and transactions, from initial request through governance readout.
• Integrate toxicology, PK/QSP, nonclinical pharmacology, and external expert input into coherent scientific assessments.
• Identify FIH-enabling gaps, translational risks, regulatory limitations, and appropriate mitigation strategies.
• Prepare due diligence reports, executive summaries, and risk tables for governance review.
• Serve as the nonclinical scientific interface for Business Development and Therapeutic Area teams.
• Improve nonclinical due diligence frameworks and templates, while mentoring junior and matrix team members.

Requirements

• Advanced degree such as a Ph.D., D.V.M., or equivalent in toxicology, pharmacology, or a related field.
• At least 10 years of experience in nonclinical development, including due diligence or external innovation.
• Strong understanding of FIH-enabling nonclinical requirements, particularly for biologics and complex modalities.
• Knowledge of the drug development process and strong knowledge of ICH and GLP.
• Experience working in cross-functional, multicultural, international, and matrix environments.
• Fluent English, both written and spoken, is required.

Nice to have

• Toxicology training or board certification.
• Experience across multiple therapeutic areas and modalities.

Culture & Benefits

• Work within a global biotherapeutics organization serving patients in more than 100 countries.
• Collaborate with international and multicultural teams across research and therapeutic areas.
• Contribute to innovation across plasma fractionation, recombinant protein technology, and cell and gene therapy platforms.
• Access CSL employee benefits and an inclusion-focused workplace.